UK-based Hikma Pharmaceuticals, a fast growing global pharmaceutical group, has posted revenue of $532.3 million for the first half of the year, marking a 34.8 per cent increase over the same period last year.

The group, with sales in more than 50 countries across Europe, Mena and the US, registered organic growth of 7.6 per cent.

Hikma continues to leverage its Jordanian and Saudi manufacturing capabilities as part of its strategy to drive future growth in the US Generics business. As of June, 27.2 per cent of its oral generics sales in the US were manufactured in Hikma’s Mena facilities.

Hikma also signed a sponsorship agreement with the National Strategic Committee for Chronic Diseases in Jordan through which it will support a campaign to combat diabetes, high blood pressure and chronic obesity.

In Tunisia, Hikma sponsored the association for the help of patients having breast cancer and participated in the corporate social responsibility day organized by AIESEC Tunis.

Mazen Darwazah, chief executive officer of Mena and vice chairman, said: “Our reputation for quality and commitment to corporate responsibility has allowed us to deliver robust growth in the first half of this year.

“I am extremely pleased with the performance of our Mena countries, and the great benefits our US and European injectables facilities are bringing in to the region. I expect the outlook to be positive for the second half of the year, and I am confident that the Group will continue to perform well.” – TradeArabia News Service